Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01746251
Recruitment Status : Active, not recruiting
First Posted : December 10, 2012
Last Update Posted : March 7, 2018
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Lecia V. Sequist, Massachusetts General Hospital

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : August 2019
  Estimated Study Completion Date : August 2019